Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 4.40 GBp
Change Today -0.10 / -2.22%
Volume 3.0M
VRP On Other Exchanges
Symbol
Exchange
London
OTC US
As of 12:09 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

verona pharma plc (VRP) Snapshot

Open
4.50 GBp
Previous Close
4.50 GBp
Day High
4.50 GBp
Day Low
4.40 GBp
52 Week High
05/21/15 - 4.88 GBp
52 Week Low
06/23/14 - 1.05 GBp
Market Cap
44.4M
Average Volume 10 Days
3.3M
EPS TTM
-0.0032 GBp
Shares Outstanding
1.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERONA PHARMA PLC (VRP)

Related News

No related news articles were found.

verona pharma plc (VRP) Related Businessweek News

No Related Businessweek News Found

verona pharma plc (VRP) Details

Verona Pharma plc, a clinical stage biopharmaceutical company, engages in the research, discovery, and development of therapeutic drugs for the treatment of acute and chronic respiratory diseases in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual phosphodiesterase 3 and 4 inhibitor that has completed Phase I and II clinical trials used for the treatment of chronic obstructive pulmonary disease and asthma, as well as in pre-clinical testing for the treatment of cystic fibrosis. It is also developing novel anti-inflammatory polysaccharides (NAIPs) that are in basic research phase to treat various respiratory and inflammatory diseases. The company is based in London, the United Kingdom.

Founded in 2005

verona pharma plc (VRP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 261.7K GBP
Chief Financial Officer and Director
Total Annual Compensation: 47.5K GBP
Executive Director and Member of Audit Commit...
Total Annual Compensation: 77.5K GBP
Compensation as of Fiscal Year 2014.

verona pharma plc (VRP) Key Developments

Verona Pharma plc Reports Audited Results for the Year Ended 31 December 2014

Verona Pharma plc reported audited results for the year ended 31 December 2014. For the year, the company reported loss after tax of £2.76 million against £2.52 million a year ago, equivalent to 0.32 pence per ordinary share against 0.74 pence per ordinary share a year ago. Net cash outflows from operating activities during the year was £3.83 million against £2.34 million a year ago.

Verona Pharma plc to Report Fiscal Year 2014 Results on May 12, 2015

Verona Pharma plc announced that they will report fiscal year 2014 results on May 12, 2015

Verona Pharma plc Announces Encouraging Interim Results from the First Part of a 120 Subject Phase I/II Clinical Trial with RPL554

Verona Pharma plc announced encouraging interim results from the first part of a 120 subject Phase I/II clinical trial with RPL554, using a new proprietary nebulised formulation. RPL554 is a novel PDE3/4 inhibitor, which is currently in development as a nebulised treatment for acute exacerbations in COPD patients in a hospital or home-care setting. The trial is being performed at the Medicines Evaluation Unit in Manchester by lead investigator Professor Dave Singh. In the first part of this study, which was successfully completed ahead of schedule, 50 healthy volunteers were enrolled in a single ascending dose study with the new drug formulation. Five dose levels were tested with the pre-specified high dose being approximately 16 times greater than the dose tested in earlier reported clinical studies, using the previous formulation of RPL554. The results from this study showed that the drug was well tolerated across all doses and no maximum tolerated dose could be defined. Importantly, there were no changes in subjects' cardiovascular parameters and there was complete absence of nausea or vomiting at all doses. Pharmacokinetic data showed lower peak plasma levels of the drug and a plasma half-life of 11-12hr, significantly longer than that of historically published data of similar doses, using the previous formulation. This suggests that the new formulation results in a longer residence time for RPL554 in the lung and slower release into the blood stream. Pulmonary residence time is an important factor in determining duration of effect.1 These results support the potential for RPL554 to be a drug administered twice-a-day and this will be further verified in the second part of the trial, which is now being initiated. In the next part of the study, multiple ascending doses given for five consecutive days will be investigated in both healthy volunteers and patients with chronic obstructive pulmonary disease (COPD). The primary objective of this study is to further confirm safety and tolerability, as well as to investigate bronchodilation in COPD patients. In studies with the previous formulation, RPL554 generated significant bronchodilation that appeared to be at least similar in effect size to that seen with salbutamol,2 a commonly used drug in the treatment of COPD. Results from this new study are expected to be available in the second half of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRP:LN 4.40 GBp -0.10

VRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VRP.
View Industry Companies
 

Industry Analysis

VRP

Industry Average

Valuation VRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERONA PHARMA PLC, please visit www.veronapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.